Q-omics provides the consensus-scored MATN2 profile across patient tissues and cancer cell-line models. MATN2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MATN2 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, MATN2 protein abundance shows 19,932 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight MESO, BLCA, and LUAD as cancer lineages where MATN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MATN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MATN2 survival associations across molecular data types. MATN2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (9) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MATN2 RNA expression–survival associations across cancer types. High MATN2 expression shows unfavorable associations in MESO, KIRP and HNSC, but favorable associations in OV, KIRC and UVM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MATN2 RNA expression.
This table summarizes MATN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MATN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MATN2 shows lower tumor expression in BLCA, THCA, COAD, KIRC, KICH and BRCA. The BLCA box plot shows higher MATN2 RNA expression in normal versus tumor tissue (log2 FC = −3.644, t-test p < 0.001).
This table shows molecular features associated with MATN2 in patient tissues and cancer cell lines. In patient samples, MATN2 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, MATN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
